Nextcure, INC

NextCure, Inc. and Avere Therapeutics, Inc. have entered into a definitive merger agreement, combining Avere's oral IL-23 program with NextCure's public infrastructure, supported by a $320 million private placement.

NextCure stockholders approved an amendment to the 2019 Omnibus Incentive Plan, increasing authorized shares and updating evergreen provisions.

NextCure announced positive Phase 1 data for its investigational drug SIM0505 at ASCO 2026, showing a 55% ORR in gynecologic cancers.

NextCure, Inc. announced its full year 2025 financial results and provided updates on its clinical-stage antibody-drug conjugate programs, SIM0505 and LNCB74, with key data readouts anticipated in 2026.

NextCure, Inc. announced preliminary year-end 2025 cash of $41.8 million and provided updates on its SIM0505 and LNCB74 antibody drug conjugate programs, including a delay for LNCB74 proof-of-concept data.

NextCure, Inc. announced an at-the-market offering agreement to sell up to $14.5 million of common stock to fund general corporate purposes and advance product candidates.

NextCure reports a net loss of $9.8 million for Q1 2026, with cash reserves dwindling, while advancing its lead drug candidates SIM0505 and LNCB74.

NextCure, Inc. reported a net loss of $8.6 million for Q3 2025 and disclosed substantial doubt about its ability to continue as a going concern, necessitating immediate capital raises.

NextCure, Inc. reported a significant increase in net loss for Q2 2025, driven by a new licensing agreement, while also disclosing substantial doubt about its ability to continue as a going concern.

NextCure, Inc. announces its Q1 2025 financial results, reporting a net loss of $10.976 million and highlighting the advancement of its LNCB74 clinical trial.

NextCure Inc. announced its third quarter 2024 results, highlighting a strategic pipeline prioritization and a cash runway extended into the second half of 2026.

NextCure, a clinical-stage biopharmaceutical company, announced its second quarter 2024 financial results, highlighting a focus on key clinical programs and a restructuring plan to extend its cash runway.

NextCure, Inc. reported continued net losses and a going concern warning for 2025, while advancing its lead antibody-drug conjugate candidates and securing additional financing.

NextCure's 2024 10-K filing highlights the company's focus on advancing LNCB74, a B7-H4 targeted ADC, and pursuing strategic partnerships for other programs.

NextCure is focusing on its lead programs, NC410 and LNCB74, while pausing manufacturing and seeking partnerships for other assets to extend its cash runway.

Avere Therapeutics, in conjunction with NextCure, has published corporate presentation detailing the development of AVR-001, a once-weekly oral IL-23 receptor antagonist for inflammatory diseases.

ADAR1 Capital Management, LLC and 1 other reported changes in beneficial ownership of NextCure, Inc. common stock on July 30, 2026.

ADAR1 Capital Management, LLC and 1 other reported changes in beneficial ownership of NextCure, Inc. common stock on July 27, 2026.

NextCure and Avere Therapeutics have entered into a merger agreement to combine, with Avere's lead drug candidate AVR-001 for inflammatory diseases as a key focus.

NextCure and Avere Therapeutics have entered into a definitive merger agreement for an all-stock transaction, combining Avere's oral IL-23 program with NextCure's public market infrastructure.

NextCure, Inc. reported a grant of 8,270 employee stock options to Senior VP and General Counsel Kevin G. Shaw with an exercise price of $10.85.

NextCure, Inc. has filed its 2026 proxy statement to solicit stockholder votes for director elections, auditor ratification, executive compensation, and an equity plan amendment.

NextCure, Inc. has engaged Campaign Management LLC to solicit proxies for its upcoming 2025 Annual Meeting of Stockholders.

NextCure, Inc. has engaged Campaign Management LLC to solicit proxies for its upcoming 2025 Annual Meeting of Stockholders.

NextCure, Inc. is holding its 2025 Annual Meeting on June 20, 2025, and is providing stockholders with information on how to vote on key proposals.

NextCure is asking stockholders to approve a reverse stock split to maintain its Nasdaq listing and is holding advisory votes on executive compensation at its 2025 annual meeting.

NextCure, Inc. will hold its annual stockholder meeting on June 20, 2024, featuring proposals including the election of directors, ratification of the company's accounting firm, and approval of an amendment to the company's certificate of incorporation.

Sofinnova Venture Partners IX and affiliates updated their beneficial ownership in NextCure, Inc. to 7.1% of common stock, reflecting dilution from recent stock sales.

SilverArc Capital Management, LLC and Devesh Gandhi have reported beneficial ownership of 4.9% of NextCure, Inc.'s Class A Common Stock as of March 31, 2026.

Simcere Pharmaceutical Group and its affiliates have disclosed a significant 9.4% passive ownership stake in NextCure, Inc., totaling 338,636 shares.

Squadron Master Fund LP and affiliated entities have disclosed a 9.99% beneficial ownership stake in NextCure, Inc. as of December 31, 2025.

Pfizer Inc. and its affiliate Pfizer Ventures (US) LLC have reported a combined beneficial ownership of 3.0% in NEXTCURE, INC. common stock.

SilverArc Capital Management and Devesh Gandhi have reported a 5.02% beneficial ownership stake in NextCure, Inc.'s Class A Common Stock.

Affinity Asset Advisors and Michael Cho have disclosed a 9.99% beneficial ownership stake in NextCure, Inc., including shares from warrants.